Skip to content
Bills from the 2017–18 session

Assembly Bill 679

The treatment of biological products for various purposes under the pharmacy practice law

Stopped before the full Assembly voted

The recommended passing it, but the full Assembly never voted on it. To try again, a lawmaker would have to start a new bill.

  1. Introduced, passed

    Nov 29, 2017

  2. Committee, passed

    Approved

  3. Assembly vote, stopped here

    Stopped here. The full Assembly never voted on it.

  4. Senate vote, not reached

  5. Governor, not reached

  6. Law, not reached

Latest entry in the official record, Mar 28, 2018: “Failed to pass pursuant to ⁠”

Read the bill

Following saves it on this device. New actions show on your Following page. You can also get updates in a feed reader.

What it would have done

Summary by the , the Legislature's nonpartisan drafting office. It's their wording, not ours.

This bill makes a number of changes to the pharmacy practice laws regarding the prescribing and dispensing of biological products, including changes to address the dispensing of interchangeable biological products.

Current state law contains a number of provisions that address the dispensing of drug product equivalents in lieu of the specific drug product described.

Read the full summary

Specifically, current law allows a pharmacist to dispense the “drug product equivalent” of a drug prescribed if the drug product equivalent is lower in price to the consumer than the drug product prescribed, unless the prescribing practitioner specifically indicates on the prescription order that no substitution of the drug product prescribed may be made. Current law defines “drug product equivalent” as a drug product that the federal Food and Drug Administration, which regulates drugs pursuant to the Federal Food, Drug, and Cosmetic Act, has determined is therapeutically equivalent to the drug product prescribed. Current law also provides that if a pharmacist, pursuant to a prescription order that specifies a drug product by its brand name, dispenses the drug product equivalent of the drug product specified in the prescription order, the label required for the drug may include both the generic name of the drug product equivalent and the brand name specified in the prescription order, unless the prescribing practitioner requests that the brand name be omitted from the label.

This bill creates provisions similar to those described above that apply with respect to biological products, which are regulated somewhat differently from other drugs by the FDA under the federal Public Health Service Act. Specifically, the bill allows a pharmacist to dispense an interchangeable biological product in lieu of the biological product prescribed if the interchangeable biological product is lower in price to the consumer than the biological product prescribed, unless the prescribing practitioner specifically indicates on the prescription order that no substitution of the biological product prescribed may be made. The bill defines “interchangeable biological product” as a biological product that the FDA has determined is therapeutically equivalent to the biological product prescribed or that the FDA has licensed and determined meets standards for interchangeability pursuant to provisions in federal law. The bill further establishes requirements for pharmacists who dispense biological products to make an entry into an electronic records system or to otherwise communicate to the prescribing practitioner regarding the biological product dispensed, subject to certain exceptions. The bill provides that if a pharmacist, pursuant to a prescription order that specifies a biological product by its brand name, dispenses the interchangeable biological product of the biological product specified in the prescription order, the label required for the drug may include both the proper name of the interchangeable biological product and the brand name specified in the prescription order.

Current law also contains provisions regarding the labeling of prescription drugs, including requirements that certain information be contained on the commercial container of a prescription drug. The bill creates a similar provision that applies only to biological products, which includes a requirement that certain information to be contained on the commercial container of the biological product, including the brand name, if any, of the biological product, and the proper name of the biological product.

The provisions newly created in the bill apply only to biological products. The bill modifies the provisions under current law that apply to drugs generally so that they apply only to drugs that are not biological products.

Who's behind it

25 lawmakers are its ⁠. 14 are Republicans and 11 are Democrats.

9 more lawmakers ⁠.

See all 34 names

Authors (25)

Signed on in support (9)

How lawmakers voted

There was one vote on this bill.

Assembly Committee on Health vote to recommend it

Passed, 11 to 0 · Mar 22, 2018

No member-by-member record exists for this vote. Committee votes and some older sessions record totals only.

Official motion: “Report passage recommended by Committee on Health, Ayes 11, Noes 0”. Official record · This vote on its own page

What happened

  1. Mar 28, 2018

    The session ended, and the bill died with it.

  2. Mar 22, 2018

    Sent to the Assembly Committee on Rules.

  3. Mar 22, 2018

    The committee voted to recommend passing it, 11 to 0.

  4. Feb 20, 2018

    2 more representatives signed on in support.

  5. Dec 13, 2017

    The committee held a public hearing.

  6. Dec 7, 2017

    1 more representative signed on in support.

  7. Nov 29, 2017

    Sent to the Assembly Committee on Health.

  8. Nov 29, 2017

    Introduced in the Assembly.

See the official record, word for word
  1. Nov 29, 2017 · Assembly

    Introduced by Representatives Rohrkaste, Spiros, Kolste, Anderson, Berceau, R. Brooks, Considine, Crowley, Felzkowski, Fields, Horlacher, Jacque, Kooyenga, Kremer, Krug, Kuglitsch, Ohnstad, Sargent, Sinicki, Skowronski, Spreitzer, Thiesfeldt, Tusler, Subeck and Edming; cosponsored by Senators Vukmir, Carpenter, Craig, Olsen, Vinehout, Bewley and Marklein

  2. Nov 29, 2017 · Assembly

    Read first time and referred to Committee on Health

  3. Dec 7, 2017 · Assembly

    Representative Bernier added as a coauthor

  4. Dec 13, 2017 · Assembly

    Public hearing held

  5. Feb 1, 2018 · Assembly

    Executive action taken

  6. Feb 20, 2018 · Assembly

    Representatives Barca and Shankland added as coauthors

  7. Mar 22, 2018 · Assembly

    Report passage recommended by Committee on Health, Ayes 11, Noes 0

  8. Mar 22, 2018 · Assembly

    Referred to committee on Rules

  9. Mar 28, 2018 · Assembly

    Failed to pass pursuant to Senate Joint Resolution 1

Terms on this page

Committee

A small group of lawmakers that looks at a bill first. Most bills never leave committee.

More in the glossary

Senate Joint Resolution 1

The session's calendar. Any bill not passed by its last voting day dies.

Official term: Failed to pass pursuant to SJR 1. More in the glossary

Legislative Reference Bureau

The Legislature's nonpartisan office that drafts bills and writes the summary at the top of each one.

Official term: LRB analysis. More in the glossary

Author

A lawmaker who formally puts a bill forward. The text itself is drafted by the Legislative Reference Bureau.

Official term: Author, coauthor. More in the glossary

Signed on in support

Lawmakers who back a bill without being one of its authors, often from the other chamber.

Official term: Cosponsor. More in the glossary

Roll call

A vote where each lawmaker's yes or no is recorded by name.

Official term: Roll call vote. More in the glossary

From the Wisconsin Legislature's official record, checked Sep 15, 2026. See the source

Committee

A small group of lawmakers that looks at a bill first. Most bills never leave committee.

Senate Joint Resolution 1

The session's calendar. Any bill not passed by its last voting day dies.

Official term: Failed to pass pursuant to SJR 1

Legislative Reference Bureau

The Legislature's nonpartisan office that drafts bills and writes the summary at the top of each one.

Official term: LRB analysis

Author

A lawmaker who formally puts a bill forward. The text itself is drafted by the Legislative Reference Bureau.

Official term: Author, coauthor

Signed on in support

Lawmakers who back a bill without being one of its authors, often from the other chamber.

Official term: Cosponsor

Roll call

A vote where each lawmaker's yes or no is recorded by name.

Official term: Roll call vote